GlassScriptPhysician profile
Abdul K Garuba
NPI 1063483113
$3,771.33
in general payments reported to CMS, 2019-2025
27 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $346 · 2021: $1,067 · 2022: $529 · 2023: $534 · 2024: $507 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $775.60 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $530.13 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $312.25 | 2019-2025 | Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $281.89 | 2019-2023 | |
| Abbvie INC. | $263.86 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.40 | 2020-2024 | Xifaxan, Trulance |
| Cranial Technologies, INC | $211.91 | 2020-2025 | Doc Band |
| Exact Sciences Corporation | $193.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $141.61 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $133.83 | 2021-2022 | |
| Abbott Laboratories | $96.42 | 2021 | |
| Scilex Pharmaceuticals INC. | $91.95 | 2021-2023 | Ztlido |
| Agios Pharmaceuticals, INC. | $80.29 | 2024-2025 | Pyrukynd |
| Paratek Pharmaceuticals, INC. | $59.06 | 2022-2023 | Nuzyra |
| Amgen INC. | $56.60 | 2024-2025 | Krystexxa, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.77 | 2021 | |
| Phadia US INC. | $40.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $40.20 | 2019-2020 | |
| Sanofi Pasteur INC. | $32.06 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $28.43 | 2019-2025 | Capvaxive |
| Phathom Pharmaceuticals, INC. | $22.31 | 2023 | Voquezna |
| Idorsia Pharmaceuticals US INC | $20.90 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $20.72 | 2020 | |
| Pfizer INC. | $20.15 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.12 | 2023 | |
| Inspire Medical Systems, INC. | $15.57 | 2025 | Inspire |
| Horizon Therapeutics Plc | $14.34 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Garuba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.